戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1          We evaluated the impact of PCV13 on pneumococcal meningitis.
2 IgR and PECAM-1 has the potential to prevent pneumococcal meningitis.
3 ironment needed to establish nonhematogenous pneumococcal meningitis.
4  means they influence the pathophysiology of pneumococcal meningitis.
5 e associated with morbidity and mortality of pneumococcal meningitis.
6 long-term hearing function in a rat model of pneumococcal meningitis.
7 in CSF specimens from patients and mice with pneumococcal meningitis.
8 ammation and potential therapeutic target in pneumococcal meningitis.
9 ions for use of adjunctive dexamethasone for pneumococcal meningitis.
10  be associated with outcome in patients with pneumococcal meningitis.
11 t of CNS inflammation in an in vivo model of pneumococcal meningitis.
12                  We identified 1379 cases of pneumococcal meningitis.
13 in play crucial roles in the pathogenesis of pneumococcal meningitis.
14 is plays in neuronal death in the context of pneumococcal meningitis.
15 rognosis for patients, especially those with pneumococcal meningitis.
16 e to the neuropathology commonly observed in pneumococcal meningitis.
17 en and adults with haemophilus meningitis or pneumococcal meningitis.
18 uggesting new neuroprotective strategies for pneumococcal meningitis.
19 ebrospinal fluid compartment in experimental pneumococcal meningitis.
20 of meningitis, with the largest increase for pneumococcal meningitis.
21 as 47% (112 of 238) and 49% (117 of 238) for pneumococcal meningitis, 46% (22 of 48) and 56% (27 of 4
22 ata from 238 patients with culture-confirmed pneumococcal meningitis, 48 with culture-confirmed tuber
23  fatality was 8% (25/329) and was higher for pneumococcal meningitis (5/26 [19%]) than GBS meningitis
24  in the cerebrospinal fluid of patients with pneumococcal meningitis (6.8 to 3,900 ng of muramic acid
25 lysis was restricted to patients with proven pneumococcal meningitis (68 of 129 patients receiving co
26                     The observed decrease in pneumococcal meningitis after PCV introduction may be in
27 h declines in the proportion of vaccine-type pneumococcal meningitis after the introduction of 13-val
28 PCV13 vaccination is effective in preventing pneumococcal meningitis among children <5 years of age i
29 genetic marker of morbidity and mortality of pneumococcal meningitis and also suggests a potential ro
30                               In conclusion, pneumococcal meningitis and herpes simplex encephalitis
31 tive, nationwide cohort of 405 patients with pneumococcal meningitis and in 329 controls matched for
32 lmost half of variation in susceptibility to pneumococcal meningitis and one-third of variation in se
33 multaneous in vivo biophotonic monitoring of pneumococcal meningitis and the accompanying neuronal in
34 5 years with H influenzae, meningococcal and pneumococcal meningitis, and septicaemia.
35 tric meningitis hospitalizations, PCV13-type pneumococcal meningitis, and severe and moderate ARI out
36               The mortality and morbidity of pneumococcal meningitis are still devastating, and resul
37 e distribution among children with confirmed pneumococcal meningitis at HCH and acute respiratory inf
38                                           In pneumococcal meningitis, bacterial growth in the cerebro
39                Following PCV10 introduction, pneumococcal meningitis, bacterial meningitis, and pneum
40                                              Pneumococcal meningitis case fatality rate was 6-fold hi
41  association study in 469 community-acquired pneumococcal meningitis cases and 2072 population-based
42                                The number of pneumococcal meningitis cases decreased by 88.1% (52/59)
43                              Nearly half the pneumococcal meningitis cases successfully serotyped (46
44         As apoptosis drives neuronal loss in pneumococcal meningitis, caspase inhibitors might provid
45                                              Pneumococcal meningitis caused by PCV13 serotypes decrea
46                               Mortality from pneumococcal meningitis decreased between 2005 (0.049 pe
47                                              Pneumococcal meningitis diagnosed by RT-PCR declined fro
48                   Also, 14% of children with pneumococcal meningitis died.
49  reducing the incidence of hearing loss from pneumococcal meningitis, especially if therapy is instit
50   We also evaluated declines in vaccine-type pneumococcal meningitis following pneumococcal conjugate
51                        We examined trends in pneumococcal meningitis from 1998 through 2005 using act
52                                              Pneumococcal meningitis had the highest case fatality ra
53            The epidemiology and treatment of pneumococcal meningitis has changed with the implementat
54                In children, the incidence of pneumococcal meningitis has decreased since the introduc
55            Their role in the pathogenesis of pneumococcal meningitis has not been addressed.
56                                     Rates of pneumococcal meningitis have decreased among children an
57   We analyzed episodes of community-acquired pneumococcal meningitis in adults (>=16 years) in the Ne
58 py have changed the incidence and outcome of pneumococcal meningitis in adults over the last two deca
59 llin-susceptible and cephalosporin-resistant pneumococcal meningitis in rabbits, staphylococcal and e
60  investigated the progression and outcome of pneumococcal meningitis in Rag1(-/-) mice lacking functi
61   To better understand the high incidence of pneumococcal meningitis in the African meningitis belt,
62 ective antibody seroprevalence in preventing pneumococcal meningitis in the meningitis belt requires
63 + 1 schedule, may improve overall control of pneumococcal meningitis in this setting.
64    Despite a substantially higher historical pneumococcal meningitis incidence in Burkina Faso, the g
65                                     In 2017, pneumococcal meningitis incidence was 2.7 overall and 10
66  role played by pneumolysin and autolysin in pneumococcal meningitis is poorly understood.
67                                              Pneumococcal meningitis is the most frequent and critica
68 te vaccine (PCV7) in 2000, but its effect on pneumococcal meningitis is unclear.
69                            Poor prognosis in Pneumococcal meningitis may be associated with high pneu
70                         In a murine model of pneumococcal meningitis, mice treated with chlorpromazin
71 ubjects (controls, n = 10) and patients with pneumococcal meningitis (n = 20) was analyzed.
72                                Patients with pneumococcal meningitis often die or have severe neurolo
73 loss, especially among adults diagnosed with pneumococcal meningitis or diagnosed at a young age, wit
74 y of being employed as a former patient with pneumococcal meningitis or herpes simplex encephalitis v
75 sabilities (particularly when diagnosed with pneumococcal meningitis or when diagnosed at a young age
76 nt pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis (PM) in US children is unknown.
77  invasive pneumococcal disease, particularly pneumococcal meningitis (PM) incidence.
78      Hearing loss is an important sequela of pneumococcal meningitis (PM), occurring in up to 30% of
79 occurring in up to 30% of patients surviving pneumococcal meningitis (PM).
80                              In experimental pneumococcal meningitis, pneumolysin colocalized with ap
81                  There has been a decline in pneumococcal meningitis post-pneumococcal conjugate vacc
82 te recent advances in antimicrobial therapy, pneumococcal meningitis remains a life-threatening disea
83                                              Pneumococcal meningitis remains a significant cause of m
84                      Despite recent advances pneumococcal meningitis remains associated with a residu
85           Subgroup analysis on patients with pneumococcal meningitis showed similar results.
86 tween multiple variants in a gene region and pneumococcal meningitis susceptibility yielded one signi
87 der to find genetic variants associated with pneumococcal meningitis susceptibility.
88 rabbit model of hearing loss in experimental pneumococcal meningitis to evaluate the therapeutic effe
89 pectively) in the progression and outcome of pneumococcal meningitis, using Kaplan-Meier survival cur
90                                              Pneumococcal meningitis was diagnosed in 77% of patients
91  of brain biopsies from patients who died of pneumococcal meningitis, we observe that pneumococci col
92                  Changes in the incidence of pneumococcal meningitis were assessed against baseline v
93         Two apparently linked fatal cases of pneumococcal meningitis were investigated.
94 st signals associated with susceptibility to pneumococcal meningitis were rs139064549 on chromosome 1
95 nctive steroid treatment is underutilized in pneumococcal meningitis, where it has shown to decrease
96 f all patients and in 39.3% of patients with pneumococcal meningitis, with an associated decrease in